UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.
Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.
The trials will assist the biotech company’s development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments – specifically, therapies using an immunotherapy platform based activated dendritic cells.
Chiltern will also be responsible for processing the data obtained during the clinical evaluation.
“I am very pleased that we have been selected to manage this high profile trial,” said Chiltern CEO Dr Jim Esinhart.
“I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome.”
Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.